OVA Peptide 257-264
(Synonyms: 鸡卵白蛋白(257-264)) 目录号 : GC33448OVA Peptide(257-264)是 OVA 的 I 类 (Kb)-限制性肽表位,由Class I MHC分子H-2Kb递呈的一种来自卵白蛋白的八聚肽。
Cas No.:138831-86-4
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
OVA肽(257-264) 使用说明: |
|
OVA抗体反应及细胞因子释放的测定[1]: |
仅供参考,应根据您的具体实验需要进行修改。 |
References: [1]. Dong X, Li B, et,al. Poria cocos polysaccharide induced Th1-type immune responses to ovalbumin in mice. PLoS One. 2021 Jan 7;16(1):e0245207. doi: 10.1371/journal.pone.0245207. PMID: 33411807; PMCID: PMC7790389. |
OVA Peptide (257-264) is an MHC Class I (Kb) -restricted OVA polypeptide epitope, an octapeptide derived from ovalbumin presented by Class I MHC molecule H-2Kb.It can be used to stimulate T cell activation and activate the immune response of CD8+ cytotoxic T lymphocytes (CTL) [1-3].
OVA peptide (257-264) (injected intradermally at the base of the tail) combined with anti-CD4-monoclonal antibody increased the number of peptide-specific CTLs and showed a higher therapeutic effect against OVA-expressing tumors in mice[4]. Spleen cells pulsed with OVA peptide (257-264)( 250 μg-1mg) are sensitive to Poria cocos polysaccharide (PCP) [5]. OVA peptide (257-264) can be used as a self-assembled nanovaccine (I-OVA NE), which enhances peptid-specific CD8+T cells and exhibits ova257-264 specific CTL activity and Th1 immune response[6]. Mice anterior chamber inoculation of OVA Peptide (257-264) (250 μg) could induceanterior chamber associated immune deviation (ACAID) as evidenced by an impaired delayed-type hypersensitivity (DTH) response[7].
References:
[1]. Wick MJ, Pfeifer JD. Major histocompatibility complex class I presentation of ovalbumin peptide 257-264 from exogenous sources: protein context influences the degree of TAP-independent presentation. Eur J Immunol. 1996 Nov;26(11):2790-9. doi: 10.1002/eji.1830261135. PMID: 8921970.
[2]. Doherty PC, Christensen JP. Accessing complexity: the dynamics of virus-specific T cell responses. Annu Rev Immunol. 2000;18:561-92. doi: 10.1146/annurev.immunol.18.1.561. PMID: 10837069.
[3]. Grolleau-Julius A, Harning EK,et,al. Impaired dendritic cell function in aging leads to defective antitumor immunity. Cancer Res. 2008 Aug 1;68(15):6341-9. doi: 10.1158/0008-5472.CAN-07-5769. PMID: 18676859; PMCID: PMC2575813.
[4]. Fujinami N, Yoshikawa T, et,al. Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model. Biochem Biophys Rep. 2016 Feb 19;5:482-491. doi: 10.1016/j.bbrep.2016.02.010. PMID: 28955856; PMCID: PMC5600353.
[5]. Dong X, Li B, et,al. Poria cocos polysaccharide induced Th1-type immune responses to ovalbumin in mice. PLoS One. 2021 Jan 7;16(1):e0245207. doi: 10.1371/journal.pone.0245207. PMID: 33411807; PMCID: PMC7790389.
[6]. Yang Y, Ge S, et,al. A novel self-assembled epitope peptide nanoemulsion vaccine targeting nasal mucosal epithelial cell for reinvigorating CD8+ T cell immune activity and inhibiting tumor progression. Int J Biol Macromol. 2021 Jul
31;183:1891-1902. doi: 10.1016/j.ijbiomac.2021.05.158. Epub 2021 May 27. PMID: 34052270.
[7]. Ren Y, Yang P, et,al. OVA-specific CD8+ T cells do not express granzyme B during anterior chamber associated immune deviation. Graefes Arch Clin Exp Ophthalmol. 2006 Oct;244(10):1315-21. doi: 10.1007/s00417-006-0255-0. Epub 2006 Mar 15. PMID: 16538449.
OVA Peptide(257-264)是 OVA 的 I 类 (Kb)-限制性肽表位,由Class I MHC分子H-2Kb递呈的一种来自卵白蛋白的八聚肽。可用来刺激T细胞活化,激活CD8+细胞毒性T淋巴细胞(CTL)的免疫应答[1-3]。
OVA Peptide(257-264)(尾底皮下注射)联合抗CD4单克隆抗体可增加多肽特异性CTL的数量,对小鼠表达OVA的肿瘤有较高的治疗效果[4]。OVA Peptide(257-264)(250 μg-1mg)脉冲脾脏细胞对茯苓多糖(PCP)敏感[5]。OVA Peptide(257-264)可以作为一种自组装纳米疫苗(I-OVA NE),它可以增强肽特异性CD8+ T细胞,并表现出OVA Peptide(257-264)特异性CTL活性和Th1免疫反应[6]。小鼠前房接种OVA Peptide(257-264)(250 μg)可诱导小鼠前房相关免疫偏差(ACAID),表现为延迟型超敏反应(DTH)反应受损[7]。
Cas No. | 138831-86-4 | SDF | |
别名 | 鸡卵白蛋白(257-264) | ||
Canonical SMILES | Ser-Ile-Ile-Asn-Phe-Glu-Lys-Leu | ||
分子式 | C45H74N10O13 | 分子量 | 963.13 |
溶解度 | 15 mg/mL in Water | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.0383 mL | 5.1914 mL | 10.3828 mL |
5 mM | 0.2077 mL | 1.0383 mL | 2.0766 mL |
10 mM | 0.1038 mL | 0.5191 mL | 1.0383 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。